Kyrgyzstan vs Macau, China: Previously treated cases tested for RR-/MDR-TB
Kyrgyzstan
95.0%
in 2024
Macau, China
96.0%
in 2024
Kyrgyzstan rank
66th
Macau, China rank
65th
Previously treated cases tested for RR-/MDR-TB over time
- Kyrgyzstan
- Macau, China
How they compare
Macau, China currently reports 96.0% against 95.0% in Kyrgyzstan, a difference of 1.0%.
The two have swapped places 2 times across 18 shared years of data; in 2005 it was Macau, China ahead.
Kyrgyzstan ranks 66th and Macau, China ranks 65th of 180 countries.
Macau, China has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Kyrgyzstan | Macau, China | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 26.4% | 66.8% | 40.4% | Macau, China |
| 2010s | 65.1% | 82.6% | 17.5% | Macau, China |
| 2020s | 93.8% | 95.4% | 1.6% | Macau, China |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher previously treated cases tested for rr-/mdr-tb, Kyrgyzstan or Macau, China?
- Macau, China, at 96.0% against 95.0% in Kyrgyzstan as of 2024.
- What is the difference in previously treated cases tested for rr-/mdr-tb between Kyrgyzstan and Macau, China?
- 1.0%, with Macau, China ahead.
- How many years of comparable data are there for Kyrgyzstan and Macau, China?
- 18 years are reported by both, from 2005 to 2024.
- How do Kyrgyzstan and Macau, China rank globally for previously treated cases tested for rr-/mdr-tb?
- Kyrgyzstan ranks 66th and Macau, China ranks 65th of 180 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as Previously treated cases tested for RR-/MDR-TB (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.